Department of Molecular Epidemiology, LUMC, Leiden, The Netherlands.
Osteoarthritis Cartilage. 2011 Sep;19(9):1091-4. doi: 10.1016/j.joca.2011.06.002. Epub 2011 Jun 16.
On November fourth and fifth 2010 a group of more than 100 international investigators gathered in Atlanta for the second Osteoarthritis (OA) Biomarkers Global Initiative workshop titled "Genetics and Genomics: New Targets in OA". The first workshop took place in April 2009 and focused on in vitro (soluble) biomarkers whilst the third and final workshop will take place in 2012 and will focus on imaging biomarkers. The OA Research Society International (OARSI) has organized the workshops. In addition to OARSI, the National Institute of Arthritis, Musculoskeletal and Skin Diseases, the Arthritis Foundation, Amgen, Genzyme, the American Orthopaedic Society for Sports Medicine and Pfizer sponsored the second meeting. It was clear from this meeting that experiments in the genetics, epigenetics and genomics of OA, are yielding valuable insights into the etiology of this heterogeneous disease but that much still needs to be learnt. Combining genetic insights with conventional biomarkers and imaging modalities may provide scientists with the enhanced tools to understand this complex disease. With those tools in hand, clinicians and industry can develop protocols to ultimately improve patient care.
2010 年 11 月 4 日和 5 日,超过 100 名国际研究人员聚集在亚特兰大,参加第二次骨关节炎(OA)生物标志物全球倡议研讨会,题为“遗传学和基因组学:OA 的新靶点”。第一次研讨会于 2009 年 4 月举行,重点是体外(可溶性)生物标志物,而第三次也是最后一次研讨会将于 2012 年举行,重点将放在成像生物标志物上。国际骨关节炎研究协会(OARSI)组织了这些研讨会。除了 OARSI 之外,美国国家关节炎、肌肉骨骼和皮肤病研究所、关节炎基金会、安进、健赞、美国运动医学骨科协会和辉瑞公司也赞助了第二次会议。从这次会议清楚地看出,OA 的遗传学、表观遗传学和基因组学实验正在为这种异质疾病的病因学提供有价值的见解,但仍有许多需要了解。将遗传见解与传统的生物标志物和成像方式相结合,可能为科学家提供增强的工具来理解这种复杂的疾病。有了这些工具,临床医生和行业可以制定协议,最终改善患者的护理。